The case for adjuvant CMF chemotherapy in breast cancer. Has it been made?
The utility of adjuvant CMF in the treatment of breast cancer has been reanalyzed. The actual percentage of patients who benefit from adjuvant CMF has been shown to be relatively small. The widespread use of adjuvant CMF must be further examined.
D001365:Axilla; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008207:Lymphatic Metastasis; D008593:Menopause; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use*
D003520:Cyclophosphamide; D005472:Fluorouracil; D008727:Methotrexate